Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether 18 F-FDG-PET/CT could predict the therapeutic response of nivolumab at the early phase. Methods Twenty-four patients were enrolled in this study. 18 F-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUV max , metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted. Results Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUV max , 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in 18 F-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that 18 F-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab. Conclusion Metabolic response by 18 F-FDG was effective in predicting efficacy and survival at 1 month a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have demonstrated that metabolic parameters such as SUVmax, metabolic tumor volume, and total lesion glycolysis can predict responses to immune checkpoint inhibitors, with elevated baseline SUVmax values associated with less favorable outcomes [7,8].”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [7]
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 12×
“Lopci et al. [14] reported a direct association betweenmetabolic parameters of 18F–FDG and the expression of immunemarkers such as PD-L1, cluster of differentiation 8 (CD8), CD68, and PD-1 in patients with NSCLC [14].”
BackgroundMethodInfluentialNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 11×
“Lopci et al. [14] reported a direct association betweenmetabolic parameters of 18F–FDG and the expression of immunemarkers such as PD-L1, cluster of differentiation 8 (CD8), CD68, and PD-1 in patients with NSCLC [14].”
BackgroundMethodInfluentialRevisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 2×
“Based on their results, PD-L1 was suggested as a novel target of HIF-1α, and simultaneous blockade of PD-L1 with the suppression of HIF-1α may be a promising approach for cancer immunotherapy [17].”
BackgroundLardinois, D., Weder, W., Hany, T. F., Kamel, E. M., Korom, S., Seifert, B., von Schulthess, G. K., & Steinert, H. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022136 · Cited by 1,416
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
Pieterman, R. M., van Putten, J. W. G., Meuzelaar, J. J., Mooyaart, E. L., Vaalburg, W., Koëter, G. H., Fidler, V., Pruim, J., & Groen, H. J. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430404 · Cited by 1,111
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Im, H.-J., Pak, K., Cheon, G. J., Kang, K. W., Kim, S.-J., Kim, I.-J., Chung, J.-K., Kim, E. E., & Lee, D. S. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2903-7 · Cited by 248
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
England, C. G., Ehlerding, E. B., Hernandez, R., Rekoske, B. T., Graves, S. A., Sun, H., Liu, G., McNeel, D. G., Barnhart, T. E., & Cai, W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177857 · Cited by 193
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179
Kaira, K., Endo, M., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Takahashi, T., Murakami, H., Tsuya, A., Nakamura, Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4662 · Cited by 159
Self-citationLopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 154
Kaira, K., Oriuchi, N., Otani, Y., Yanagitani, N., Sunaga, N., Hisada, T., Ishizuka, T., Endo, K., & Mori, M. (2007) · CHEST Journal · doi:10.1378/chest.06-2160 · Cited by 138
Self-citationSunaga, N., Oriuchi, N., Kaira, K., Yanagitani, N., Tomizawa, Y., Hisada, T., Ishizuka, T., Endo, K., & Mori, M. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.012 · Cited by 126
Self-citationChang, Y., Yang, C., Lin, M., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.012 · Cited by 126
Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer
Kaira, K., Serizawa, M., Koh, Y., Takahashi, T., Yamaguchi, A., Hanaoka, H., Oriuchi, N., Endo, M., Ohde, Y., Nakajima, T., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.025 · Cited by 123
Self-citationKaira, K., Oriuchi, N., Otani, Y., Shimizu, K., Tanaka, S., Imai, H., Yanagitani, N., Sunaga, N., Hisada, T., Ishizuka, T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1294 · Cited by 108
Self-citationPET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
Pauleit, D. O., Stoffels, G., Schaden, W., Hamacher, K., Bauer, D., Tellmann, L., Herzog, H. R., Bröer, S., Coenen, H. H., & Langen, K. (2005) · PubMed · Cited by 106
Moon, S. H., Cho, S.-H., Park, L. C., Ji, J. H., Sun, J., Ahn, J. S., Park, K., Choi, J. Y., & Ahn, M. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2400-4 · Cited by 65
Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents
Giglio, B. C., Fei, H., Wang, M., Wang, H., He, L., Feng, H., Wu, Z., Lu, H., & Li, Z. (2017) · Theranostics · doi:10.7150/thno.19371 · Cited by 38
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Higuchi, M., Owada, Y., Inoue, T., Watanabe, Y., Yamaura, T., Fukuhara, M., Hasegawa, T., & Suzuki, H. Y. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0998-y · Cited by 28
L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations.
Jager, P. L., Groen, H. J. M., van der Leest, A. H. D., van Putten, J., Pieterman, R., de Vries, E. G. E., & Piers, D. (2001) · PubMed · Cited by 18
Sachpekidis, C., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001039 · Cited by 5
Cited by
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.001 · Cited by 347
Aide, N., Hicks, R. J., Le Tourneau, C., Lheureux, S., Fanti, S., & Lopci, E. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 263
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Bai, J.-W., Qiu, S.-Q., & Zhang, G.-J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01366-y · Cited by 210
Mu, W., Tunali, I., Gray, J. E., Qi, J., Schabath, M. B., & Gillies, R. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04625-9 · Cited by 194
Metadata
- Authors
- Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., Hisada, T., Kitano, S., Obinata, H., Yokobori, T., Mori, K., Nishiyama, M., Tsushima, Y., & Asao, T.
- Affiliations
- Gunma University (JP)
- Hidaka Hospital (JP)
- Gunma University Hospital (JP)
- National Cancer Center Hospital (JP)
- Gunma University Initiative for Advanced Research (JP)
- Shizuoka Cancer Center (JP)
- Corresponding author
- Kaira, Kyoichi
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2017-08-21
- Volume
- 45
- Issue
- 1
- Pages
- 56-66
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2749460173
- Cited by
- 195
- References
- 28
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 16 · 2023: 19 · 2022: 23 · 2021: 38 · 2020: 36 · 2019: 35 · 2018: 10 · 2017: 2
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K09945)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, non-small cell lung cancer, 18F-FDG PET/CT, early treatment response prediction, PD-1 inhibitors, SUVmax, metabolic tumor volume, total lesion glycolysis, PD-L1 expression, tumor-infiltrating lymphocytes, prognostic factors
- MeSH terms
- Positron Emission Tomography Computed Tomography, Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Predictive Value of Tests, Radiopharmaceuticals, Fluorodeoxyglucose F18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.